Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer

Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 1387-1394

  Dallinger, Claudia ^a   Trommeshauser, Dirk ^a   Marzin, Kristell ^a   Liesener, Andre ^a   Kaiser, Rolf ^a   Stopfer, Peter ^a,b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b American College of Clinical Pharmacology   (Australia)

Author keywords

bioavailability; cancer patients; healthy volunteers; nintedanib; pharmacokinetics

Indexed keywords

GELATIN; NINTEDANIB; PLACEBO;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; FEMALE; FIRST PASS EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ABSORPTION TIME; MONOTHERAPY; MULTIPLE DRUG DOSE; RENAL CLEARANCE; REPEATED DRUG DOSE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; VOLUME OF DISTRIBUTION AT STEADY-STATE;

EID: 84990197058     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.752     Document Type: Article

References (19)

1. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–4782.
2. Kutluk Cenik B, Ostapoff KT, Gerber DE, Brekken RA. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther. 2013;12(6):992–1001.
3. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349(2):209–220.
4. European Medicines Agency. Vargatef (nintedanib): summary of product characteristics (2015). www.ema.europa.eu. Accessed November 16, 2015.
5. Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011;41(4):297–311.
6. Bousquet G, Alexandre J, Le Tourneau C, et al. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer. 2011;105(11):1640–1645.
7. Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res. 2010;16(10):2881–2889.
8. Gori B, Ricciardi S, Fulvi A, Intagliata S, Del Signore E, de Marinis F. New antiangiogenics in non-small cell lung cancer treatment: Vargatef (BIBF 1120) and beyond. Ther Clin Risk Manag. 2011;7:429–40.
9. Stopfer P, Roth W, Mross K. Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients. Paper presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 7-10, 2006; Prague, Czech Republic.
10. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2010;16(1):311–319.
11. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155.
12. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
13. Kropff M, Kienast J, Bisping G, et al. An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma. Anticancer Res. 2009;29(10):4233–4238.
14. Lee CP, Taylor NJ, Attard G, et al. Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors. Oncologist. 2015;20(4):368–369.
15. Okamoto I, Kaneda H, Satoh T, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther. 2010;9(10):2825–2833.
16. Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011;50(9):551–603.
17. Boehringer Ingelheim International GmbH. Full prescribing information (2014). http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf. Accessed November 16, 2015.
18. Speed B, Bu HZ, Pool WF, et al. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos. 2012;40(3):539–555.
19. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35(8):692–706.